CKD prevalence in elderly and the eGFR inflation effect, a very important paper in the @ndt-era.bsky.social . Not just for elderly but also for the young CKD population

academic.oup.com/ndt/article/...

#nephinp
#nephrology_in_practice

A must read comprehensive article @ndt-era.bsky.social focusing on the biology/genetics of kidney stone. It highlights GWASs of calcium and phosphate handling (e.g., SLC34A1, CYP24A1, CaSR) and crystallization inhibitors (e.g., UMOD, pyrophosphate-related genes).
academic.oup.com/ndt/article-...

The subdistribution hazard ratios for progressive kidney dysfunction are shown for each drug group compared with their respective propensity score–matched cohort. The blue dots represent the hazard ratio and 95% CIs. Due to wide confidence intervals, MET inhibitors results reported in the text and not displayed here. MET inhibitors are included in overall treated group. Model is adjusted for hypertension, diabetes, ischemic heart disease, congestive heart failure, chronic obstructive pulmonary disease, cirrhosis, age, sex, race, body mass index, and eGFR before drug start. ALK indicates anaplastic lymphoma kinase; BRAF, B-Raf proto-oncogene, serine/threonine kinase; CDK4/6, cyclin dependent kinase 4 or 6; EGFR, endothelial growth factor receptor; ERBB2, human epidermal growth factor receptor 2; PARP, poly(adenosine diphosphate-ribose) polymerase; VEGFR, vascular endothelial growth factor receptor.

large cohort study of
CDK 4/6
BRAF
EGFR
VEGF
and other cancer treatments

#OncoNephrology #NephSky #KidneyWk

jamanetwork.com/journals/jam... from Shuchi Anand et al from @stanfordmedicine.bsky.social

Now live in #ASNJASN, simultaneously published with #KidneyWk: "Immunosuppression in Older Kidney Transplant Recipients: A Randomized Controlled Trial"

Read more: kidney.pub/JASN0924

JAMA graph shows association of eGFR difference with risks of long-term adverse outcomes. Hazard ratio vs. difference between eGFRcys & eGFRcr (%). Lines for death, CVD death, heart failure, ASCVD, KFRT are plotted. Declining risk as difference approaches zero.

Among more than 800 000 CKD-PC participants, discordance between cystatin C and creatinine eGFR values was associated with increased risk of death, cardiovascular events, and kidney failure.

#KidneyWK @asnkidney.bsky.social

ja.ma/4oV4DtU

In celebration of #KidneyWk, the entire November issue is FREE to access until November 30, 2025!

Check out the plain-language summaries on what inspired each study, the basic approach taken, what was learned, and why it matters:

bit.ly/3X1XpZj

Last Month in Nephrology

Thoughtful and controversial blog from Last Month in Nephrology #NephSky #MedSy

Albuminuria as an ESKD surrogate may be a statistical mirage, limited by imprecision and overinterpretation

However, it moved nephrology forward and made studies happen
lastmonthinnephrology.wordpress.com

NephJC Shorts: MCD and FSGS Outcomes — NephJC A NephJC Shorts discussion of the long term data on kidney failure in FSGS and MCD

🤔 How often is end-stage kidney disease in patients with MCD/ FSGS? #NephSky #MedSky

@brianrifkin.bsky.social dissected the conclusions from the RaDar study in this #NephJCshorts

*the original article from @asnpublications.bsky.social

www.nephjc.com/news/nephjc-...

Mind The Gap: When eGFR Creatinine and Cystatin C Disagree — NephJC This week, we will discuss the clinical significance of eGFRdiff, the difference in eGFRcys (cystatin C) and eGFRcr (creatinine).

On 7/22/25 at 9pm EST only on Bluesky!
#NephSky #MedSky join us for a lively discussion.
We're debating eGFRdiff (the gap that is sometimes present between the eGFR of cystatin C and creatinine). What does it mean, what causes it and what you should do about it. #NephJC
www.nephjc.com/news/egfrdiff

Read this piece from the ERAKI working group at the @ndt-era.bsky.social regarding the results of the DEFENDER trial published last August @jama.com
academic.oup.com/ndt/article/...

Introducing NephJC Shorts — NephJC In just over a decade of critical appraisal on NephJC, we have done several experiments. Some of them have worked out phenomenally well, such as the Freely Filtered podcast. Others were not ready for ...

We don’t get to discuss every important study that comes out on #NephJC

Hence #NephJCShorts

www.nephjc.com/news/nephjc-...

Clinical Trials (ISN-ACT) - International Society of Nephrology The ISN-Advancing Clinical Trials (ISN-ACT) is an ISN initiative to encourage existing infrastructures within ISN to improve the global nephrology community’s participation in clinical trial research.

Enjoy the latest edition of ISN-ACT Global Trials Focus (GTF), a monthly list identifying and summarizing recent interesting trials relevant to kidney disease. Each trial is reviewed in context and assessed for its risk of bias in key areas ➡ http://lite.spr.ly/6

On the #AJKDBlog, catch up on these interviews with:

- Oshozimhede E. Iyalomhe on statin use in CKD
- Roger Rodby and William Whittier about renal tubular acidoses
- Subhash Chander on urea as a tool for managing SIADH-induced hyponatremia

bit.ly/3ztk4VV (FREE)

Kathy Tuttle, MD - New Approaches to Blocking Aldosterone & Angiotensinogen for Hypertension or CKD YouTube video by University of Washington Division of Nephrology

Dr. Katherine Tuttle focuses her educational Grand Rounds talk on a reemerging topic: "New Approaches to Blocking #Aldosterone & #Angiotensinogen for #Hypertension or #CKD." #kidney #nephrology #nephsky
@uwmedicine.bsky.social

youtu.be/TeWkmCopuzk

Visual Abstract

When @rajmehrotra.bsky.social is giving a talk on the factors for home dialysis stagnation and growth in US at the #CSNAGM

We get to see a CJASN abstract! From Divya Bajpai

📣 Reminder!
ASDIN is accepting applications for the $25K Research Grant in Vascular Access — but don’t wait!
🗓 Applications close July 15, 2025.

Click here to learn more: www.asdin.org/news/699844/...

#vascularaccess #ASDIN #researchgrant #nephrology

Use of SGLT2 inhibitors (SGLT2i) in ADPKD is not "presently" recommended, because people with ADPKD have been excluded from the clinical trials; thus, its safety has not been evaluated (from @kdigo.org)
#Nephpearls #NephSky

👉 kdigo.org/guidelines/a...

Finerenone reduced kidney and cardiovascular events in CKD and T2D patients, regardless of frailty. Benefits included lower albuminuria and slower eGFR decline, supporting its use even in frail individuals.

#podocytetalk #Nephpearls #Nephrology #CKD

journals.lww.com/cjasn/abstra...

EU Approves Sparsentan for Treatment of IgAN | Docwire News The European Commission has granted standard approval to sparsentan for the treatment of adults with primary IgA nephropathy (IgAN).

Sparsentan is now approved for the treatment of IgAN in European Union countries. #igan #iganephropathy #kidneydisease #nephrology #nephsky www.docwirenews.com/post/eu-appr...

SGLT2 Inhibitors and Risk for Hyperkalemia Among Individuals Receiving RAAS Inhibitors This cohort study evaluates the association between sodium-glucose cotransporter 2 inhibitors and hyperkalemia in individuals with diabetes, heart failure, or chronic kidney disease receiving renin-an...

SGLT2 Inhibitors and Risk for Hyperkalemia Among Individuals Receiving RAAS Inhibitors

jamanetwork.com/journals/jam...

Do you prescribe SGLT2 inhibitors (SGLT2i) for patients with ADPKD?
#Nephpearls #AskRenal #NephSky

❤️ LIKE for YES (and why?)
❌ X for NO (and why?)

👉 pubmed.ncbi.nlm.nih.gov/39099568/

Patient and Health Care Provider Perspectives on Showering for Patients With Hemodialysis Central Venous Catheters: A Survey Study Patients on hemodialysis using a central venous catheter (CVC) are often advised not to shower due to infection risk. This study assessed practices and attitudes of patients and health care providers ...

Do you allow hemodialysis patients with permanent HD catheters to shower?
Yes
No
Other, please state
www.ajkd.org/article/S027...
#nephinp
#nephrology_in_practice
@ajkd.bsky.social

Progress, challenges, and pragmatic concessions in predicting relative risk of kidney survival in ARPKD

doi.org/10.1016/j.kint.2025.02.018

Original article: doi.org/10.1016/j.kint.2025.01.023

#KICommentary #MedSky #NephSky #polycystickidneydisease

Alternative complement pathway dysregulation in CKD and CKD progression, endothelial inflammation and cardiovascular outcomes… room for complement inhibitors beyond complement-mediated kidney diseases?

www.jci.org/articles/vie...

#NephSky #MedSky

Editorial by Harshil A. Fichadiya and John C. Lieske:

Do Topiramate and Zonisamide Cause Kidney Stones?

bit.ly/FichadiyaED25 (FREE)

#KIControversies in Nephrology
Clinical utility of donor-derived cell-free DNA 🧬testing for kidney transplant monitoring in selected patients
You can read the
✅Point
✅Counterpoint
✅Editor's summary
in the May issue of KI
doi.org/10.1016/j.kint.2025.01.039

#MedSky #NephSky #kidneytransplant

When to use spironolactone, eplerenone or finerenone in the spectrum of cardiorenal diseases ABSTRACT. Kidney disease frequently coexists with cardiovascular (CV) diseases, and this dual presence significantly amplifies the risk of adverse clinical

When to use spironolactone, eplerenone or finerenone in the spectrum of cardiorenal diseases
academic.oup.com/ndt/article/...
An amazing article from the high impact articles published by @ndt-era.bsky.social

Stopping Versus Continuing Metformin in Patients With Advanced CKD: A Nationwide Scottish Target Trial Emulation Study

bit.ly/3ZdrYxb #OpenAccess

#VisualAbstract #CKD

#nephsky

Despite my ranking, I am still getting both winners at the finals.. @nephmadness.bsky.social